பெரியோபரேட்டிவ் ஆராய்ச்சி இல் ப்ரிகாம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from பெரியோபரேட்டிவ் ஆராய்ச்சி இல் ப்ரிகாம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In பெரியோபரேட்டிவ் ஆராய்ச்சி இல் ப்ரிகாம் Today - Breaking & Trending Today

AcelRx Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results


AcelRx Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results
Full year 2020 revenues of $5.4 million compared to $2.3 million in 2019
News provided by
Share this article
Share this article
REDWOOD CITY, Calif., March 15, 2021 /PRNewswire/  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today reported its fourth quarter and full year 2020 financial results.
Last year we achieved many important milestones and objectives that set the foundation for the growth of DSUVIA® in 2021 and beyond, despite the global pandemic, said Vince Angotti, Chief Executive Officer of AcelRx. Like many other companies in our space, COVID has had an impact on the pace of approvals and adoption of DSUVIA as formulary review meetings and elective surgeries have been postponed.  However, with vaccine ....

United States , Michael Wolff , Christian Tvetenstrand , Zimmer Biomet , Vince Angotti , Richardd Urman , Koth Cassavaugh , Department Of Defense Do , Harvard Medical School , University Hospitals Cleveland Medical Center , Perioperative Research At Brigham , Acelrx Pharmaceuticals Inc , Us Army , Reconstructive Surgery Center , Us Army Skos , Acelrx Pharmaceuticals , Chief Executive Officer , Recent Highlights , Associate Professor , Perioperative Research , Harvard Medical , Opioid Use , Reduced Time , Sublingual Sufentanil , Ambulatory Surgery Setting , Clinical Anesthesia ,

AcelRx Announces Year-End 2020 Metrics and Review of 2020 Achievements


Share this article
Share this article
REDWOOD CITY, Calif., Jan. 14, 2021 /PRNewswire/  AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced preliminary unaudited financial results and other information in connection with its participation in investor presentations, meetings and events during the week of the 39
th Annual J.P. Morgan Healthcare Conference. The Company will post its revised corporate presentation in the investor section of its website.
Key Highlights of 2020
DSUVIA® achieved Milestone C approval from the Department of Defense (DoD), a decision that approves DSUVIA for use in all U.S. Army sets, kits and outfits (SKOs). Initial stocking orders have begun for U.S. Army SKOs and are expected to approximate $30 million over the next three years, dependent on troop deployment schedules. ....

United States , Michael Wolff , Christian Tvetenstrand , Zimmer Biomet , Vince Angotti , Richardd Urman , Koth Cassavaugh , Department Of Defense Do , European Commission , Harvard Medical School , Exchange Commission , Perioperative Research At Brigham , Acelrx Pharmaceuticals Inc , Us Army , Us Army Skos , Acelrx Pharmaceuticals , Associate Professor , Perioperative Research , Harvard Medical , Opioid Use , Reduced Time , Sublingual Sufentanil , Ambulatory Surgery Setting , Clinical Anesthesia , Pain Management , Wolff Study ,